Ultrasound may spot breast cancer treatment success early
NCT ID NCT05957042
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 21 times
Summary
This study aimed to see if contrast-enhanced ultrasound (CEUS) could predict how well triple-negative breast cancer patients respond to chemotherapy and immunotherapy earlier than standard scans. No participants were enrolled, so the study was withdrawn. The goal was to find a faster, safer way to check treatment effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Penn State Health College of Medicine
Hershey, Pennsylvania, 17033, United States
Conditions
Explore the condition pages connected to this study.